Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression

Abstract

Background There is an urgent need to improve efficacy of chemotherapeutics to overcome resistance in cancer treatment. Sphingosine kinase-2 (SphK2) a key regulator of sphingolipid signaling has been rationalized as an important therapeutic target. We evaluated the role of SphK2 in doxorubicin (DOX)-induced apoptosis of NSCLC cells via altering c-FLIPS, MCL-1 and survivin expressions in order to overcome chemoresistance.

Methods Proliferation and apoptosis were evaluated by MTT assay and DAPI staining, respectively. Cell population in each phase of cell cycle was determined by flow cytometric assay. Gene and protein expression levels were examined by quantitative RT-PCR and western blot analysis, respectively.

Results Phorbol myristate acetate (PMA), a SphK2 stimulator, decreased cell death induced by IC₅₀ of DOX (1.1 µM) to around 70% (p<0.01). Cell cycle analysis revealed a significant accumulation of the cells in S phase with a marked decrease in sub G1 phase when we incubated the cells with combined treatment of PMA and DOX (p<0.05). Adding ABC294640 (40 µM), a SphK2 inhibitor, significantly abolished PMA effect on cell survival (p<0.01). Survivin expression was significantly diminished by applying ABC294640 either alone or in DOX treated cells followed by increase in cell death (p<0.05), however, there was no significant change in MCL-1 expression by ABC294640 either alone or in DOX treated cells (p=0.16) and (p=0.06), respectively.

Conclusion Identifying cancer patients with high SphK2 expression and then inhibiting of SphK2 activity can be considered as an important strategy to increase the efficacy of DOX in the induction of apoptosis.

Key words

Doxorubicin - ABC294640 - PMA - c-FLIPS - Survivin - MCL-1 - apoptosis

Publikationsverlauf

Eingereicht: 06. Mai 2017

Angenommen: 18. Juli 2017

Artikel online veröffentlicht:
26. September 2017

• References

• 1 Siegel R, Ma J, Zou Z. et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
• 2 Lemjabbar-Alaoui H, Hassan OU, Yang YW. et al. Lung cancer: Biology and treatment options. Biochim Biophys Acta 2015; 1856: 189-210
• 3 Cetin K, Ettinger DS, Hei Yj. et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clinical Epidemiology 2011; 3: 139-148
• 4 Lu C, Shao C, Cobos E. et al. Chemotherapeutic sensitization of leptomycin b resistant lung cancer cells by pretreatment with doxorubicin. PLoS ONE 2012; 7: e32895
• 5 Antoon JW, White MD, Slaughter EM. et al. Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biology & Therapy 2011; 11: 678-689
• 6 Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 2011; 9: 1509-1519
• 7 Li J, Guan HY, Gong LY. et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008; 14: 6996-7003
• 8 Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 2013; 280: 5317-5336
• 9 Ding X, Chaiteerakij R, Moser CD. et al. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 2016; 7: 20080-20092
• 10 Chen W, Bai L, Wang X. et al. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 2010; 77: 416-423
• 11 Ye Q, Cai W, Zheng Y. et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014; 33: 1828-1839
• 12 Kreuz S, Siegmund D, Scheurich P. et al. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964-3973
• 13 Gao P, Peterson YK, Smith RA. et al. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 2012; 7: e44543
• 14 Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol 2012; 34: 176-184
• 15 Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2013; 332: 141-150
• 16 Safa AR, Pollok KE. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers 2011; 3: 1639-1671
• 17 Safa AR. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. J Carcinog Mutagen 2013; Suppl 6
• 18 Wang X, Chen W, Zeng W. et al. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 2008; 7: 1156-1163
• 19 Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005; 280: 19401-19409
• 20 Ueffing N, Schuster M, Keil E. et al. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008; 112: 690-698
• 21 Reiner T, Pozas A, Parrondo R. et al. Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage. Oncoscience 2015; 2: 703-715
• 22 Song L, Coppola D, Livingston S. et al. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005; 4: 267-276
• 23 Inuzuka H, Fukushima H, Shaik S. et al. Mcl-1 Ubiquitination and Destruction. Oncotarget 2011; 2: 239-244
• 24 Toge M, Yokoyama S, Kato S. et al. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer. Int J Oncol 2015; 46: 1844-1848
• 25 Singh N, Krishnakumar S, Kanwar RK. et al. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today 2015; 20: 578-587
• 26 Huang J, Lyu H, Wang J. et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett 2015; 366: 160-172
• 27 Nakahara T, Kita A, Yamanaka K. et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021
• 28 Wang Q, Li J, Li G. et al. Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer. Tumour Biol 2014; 35: 363-368
• 29 Pfaffl MW. AZ of Quantitative PCR, Chapter 3–Quantification strategies in real-time PCR. International University Line (IUL). La Jolla. Editors, SA Bustin. 2004.
• 30 Ghanbari P, Mohseni M, Tabasinezhad M. et al. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol 2014; 174: 667-681
• 31 Calviello G, Di Nicuolo F, Serini S. et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 2005; 55: 12-20
• 32 Sabzichi M, Hamishehkar H, Ramezani F. et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pacific Journal of Cancer Prevention 2014; 15: 5311-5316
• 33 Tang X, Wang H, Fan L. et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radical Biology and Medicine 2011; 50: 1599-1609
• 34 Oliva JL, Caino MC, Senderowicz AM. et al. S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J Biol Chem 2008; 283: 5466-5476
• 35 Seo KS, Kim JS, Park KS. et al. PMA synergistically enhances apicularen A-induced cytotoxicity by disrupting microtubule networks in HeLa cells. BMC Cancer 2014; 14: 36
• 36 Black JD. Protein kinase C-mediated regulation of the cell cycle. Front Biosci 2000; 5: D406-D423
• 37 Nakagawa M, Oliva JL, Kothapalli D. et al. Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21. J Biol Chem 2005; 280: 33926-33934
• 38 Johnson KR, Becker KP, Facchinetti MM. et al. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem 2002; 277: 35257-35262
• 39 Ding G, Sonoda H, Yu H. et al. Protein Kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. Journal of Biological Chemistry 2007; 282: 27493-27502
• 40 Hait NC, Bellamy A, Milstien S. et al. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem 2007; 282: 12058-12065
• 41 Liu H, Toman RE, Goparaju SK. et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003; 278: 40330-40336
• 42 Maceyka M, Sankala H, Hait NC. et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280: 37118-37129
• 43 Kang YC, Kim KM, Lee KS. et al. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 2004; 11: 1287-1298
• 44 Takabe K, Paugh SW, Milstien S. et al. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-195
• 45 Wattenberg BW, Pitson SM, Raben DM. The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J Lipid Res 2006; 47: 1128-1139
• 46 Venkata JK, An N, Stuart R. et al. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014; 124: 1915-1925
• 47 Kelly RJ, Thomas A, Rajan R. et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology 2013; 24: 2601-2606